Back to search

Article

CXCR2 inhibition enables NASH-HCC immunotherapy

2022-02-25

Abstract excerpt

<h4>Objective</h4> Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune checkpoint inhibition (ICI). We hypothesised that targeting neutrophils using a CXCR2 small molecule inhibitor may sensitise NASH-HCC to ICI therapy. <h4>Design</h4> Neutr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
16a39b81-1c7c-56e3-b377-484d4dd5cc3a
DOI
10.1101/2022.02.24.481779
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CXCR2 inhibition enables NASH-HCC immunotherapyDOI 10.1101/2022.02.24.481779
Select a neighboring publication to make it the new centre.